Welcome to our dedicated page for GSK PLC SEC filings (Ticker: GSK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for GSK plc (GSK) provides access to the company’s regulatory disclosures as a foreign private issuer. GSK files an annual report on Form 20-F and frequent current reports on Form 6-K under the Securities Exchange Act of 1934. These documents, together with information on American Depositary Shares listed on the New York Stock Exchange, form a key source of official information for investors analyzing GSK stock.
Recent Form 6-K filings include multiple transaction notifications for persons discharging managerial responsibilities (PDMRs) and persons closely associated with them. These reports detail acquisitions of ordinary shares or American Depositary Shares, often through dividend reinvestment plans, share reward plans or the exercise of options under GSK’s share save arrangements, and specify trade dates, prices, volumes and trading venues such as the London Stock Exchange and New York Stock Exchange.
Other 6-K filings report total voting rights, including the number of issued ordinary shares, treasury shares and the resulting total voting rights figure. This information helps shareholders determine whether they must notify changes in their holdings under applicable disclosure rules. Additional 6-K submissions incorporate press releases on significant product approvals, clinical trial results and agreements, such as approvals for Exdensur (depemokimab), Nucala (mepolizumab) in COPD, Shingrix prefilled syringe presentations, and positive phase III results for bepirovirsen in chronic hepatitis B.
On Stock Titan, these filings are complemented by AI-powered summaries that explain the practical meaning of each document. Investors can quickly understand insider dealing reports, changes in capital structure, and major regulatory or clinical events without reading every line of the original filing. Real-time updates from EDGAR ensure that new GSK 6-K submissions, as well as the annual 20-F, appear promptly, while insider transactions analogous to Form 4 in the US domestic context are captured through the PDMR transaction notifications.
By using this page, users can review GSK’s historical and current SEC filings, track patterns in executive and director share dealings, and connect clinical and regulatory announcements to their formal disclosure record, all with the support of AI-generated explanations.
GSK plc reported a share buyback transaction executed via BNP Paribas SA, purchasing 175,000 ordinary shares on 31 October 2025. Prices ranged from 1,760.00p to 1,791.50p with a volume‑weighted average price of 1,780.09p. The shares will be held as Treasury shares as part of the Company’s existing buyback programme under a non‑discretionary agreement announced on 30 September 2025. Since 30 September 2025, the Company has purchased 7,303,500 shares.
After this purchase, GSK holds 254,768,344 shares in treasury and has 4,060,655,255 ordinary shares in issue (excluding treasury). The total number of voting rights is 4,060,655,255, and treasury shares represent 6.27% of voting rights. The filing also provides a venue‑level breakdown and individual trade details for trades on XLON, CHIX and BATE.
GSK plc reported a daily share repurchase under its existing buyback programme. On 30 October 2025, the company bought 180,000 ordinary shares at prices between 1,726.50p and 1,780.00p, with a volume-weighted average price of 1,756.23p. The shares will be held as treasury shares.
Since 30 September 2025, GSK has purchased 7,128,500 ordinary shares. Following this transaction, GSK holds 254,593,344 ordinary shares in treasury and has 4,060,827,442 ordinary shares in issue (excluding treasury shares). The total number of voting rights is 4,060,827,442, and the percentage of voting rights attributable to treasury shares is 6.27%.
GSK plc repurchased 180,000 ordinary shares on
Since
GSK plc reported a routine share repurchase under its existing buyback programme. On 28 October 2025, the company bought 320,000 ordinary shares at prices between 1,634.00p and 1,655.00p, with a volume‑weighted average price of 1,644.29p. The shares will be held as treasury shares and the purchases were executed by BNP Paribas SA under a non‑discretionary agreement announced on 30 September 2025.
Since 30 September 2025, GSK has purchased 6,768,500 shares. Following this transaction, GSK holds 254,233,344 shares in treasury and has 4,061,187,442 shares in issue (excluding treasury shares), which is also the total number of voting rights. The percentage of voting rights attributable to treasury shares is 6.26%. Aggregated venue volumes for the day were BATE 44,453, CHIX 44,604, and XLON 230,943.
GSK reported a strong Q3, with turnover of £8,547 million (+8% CER) and Core EPS of 55.0p (+14% CER). Total operating profit and Total EPS rose by over 100%, helped by lower Significant legal expenses, lower CCL charges and higher other operating income. Cash generated from operations was £2,520 million and free cash flow was £1,246 million.
Growth was broad-based: Specialty Medicines £3,409 million (+16% CER) led by HIV (£1,944 million, +12% CER) and Oncology (£511 million, +39% CER); Vaccines £2,678 million (+2% CER) with Shingrix £830 million (+13% CER) and Arexvy £251 million (+36% CER); General Medicines £2,460 million (+4% CER) with Trelegy £736 million (+25% CER). GSK upgraded 2025 guidance at CER to turnover growth of 6–7%, Core operating profit growth of 9–11%, and Core EPS growth of 10–12%. The company declared a 16p Q3 dividend (64p expected for 2025) and has spent £1.1 billion YTD toward its £2 billion share buyback.
GSK plc reported a transaction in its own shares as part of its existing buyback programme. On 27 October 2025, acting through BNP Paribas SA, the company purchased 166,000 ordinary shares at prices between 1,632.50p and 1,645.00p, with a volume‑weighted average price of 1,637.64p. The shares will be held as Treasury shares.
Since 30 September 2025, GSK has purchased 6,448,500 ordinary shares under the programme. Following this purchase, GSK holds 253,913,344 shares in treasury and has 4,061,507,442 ordinary shares in issue (excluding treasury shares). The total number of voting rights is 4,061,507,442, and the percentage of voting rights attributable to treasury shares is 6.25%.
The filing also lists aggregated venue data (XLON, CHIX, BATE) for the day’s trades and provides media and investor relations contacts.
GSK plc reported that its B7-H3–targeted antibody-drug conjugate, GSK5764227 (GSK'227), received Orphan Drug Designation from the European Medicines Agency for treating pulmonary neuroendocrine carcinoma, a group that includes small‑cell lung cancer. The designation is based on preliminary phase I ARTEMIS-001 data showing durable responses in extensive‑stage SCLC.
This marks the fourth regulatory designation for GSK'227. The program previously secured EMA PRIME for relapsed or refractory ES‑SCLC and two US FDA Breakthrough Therapy Designations for relapsed or refractory ES‑SCLC and late‑line relapsed or refractory osteosarcoma. GSK began a global phase III trial in relapsed ES‑SCLC in August 2025.
SCLC remains a high‑need cancer, with an estimated 250,000 diagnoses and about 200,000 deaths annually worldwide. GSK holds exclusive worldwide rights to GSK'227 outside mainland China, Hong Kong, Macau, and Taiwan.
GSK plc repurchased 555,000 ordinary shares on 24 October 2025 through BNP Paribas SA under its non‑discretionary buyback agreement. The company paid a volume‑weighted average price of 1,619.90p per share, within a range of 1,597.50p to 1,638.50p, and will hold the shares as treasury stock.
Since 30 September 2025, GSK has bought 6,282,500 ordinary shares as part of the programme. After this transaction, GSK holds 253,747,344 shares in treasury and has 4,061,673,442 shares in issue (excluding treasury), which is also the total number of voting rights. The company confirms the percentage of voting rights attributable to treasury shares is 6.25 per cent.
GSK announced US FDA approval of Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for adults with relapsed or refractory multiple myeloma after at least two prior therapies, including a PI and an IMID.
The approval is supported by phase III DREAMM-7, where the BVd combination cut the risk of death by
Blenrep is described as the only anti-BCMA agent accessible across community settings and will be available under a new streamlined REMS. Follow-up for overall survival in DREAMM-7 and -8 continues, with data expected in early
GSK plc repurchased 366,000 ordinary shares on 23 October 2025 under its existing buyback programme via BNP Paribas SA. The purchases were made between 1,640.00p and 1,657.50p per share, with a volume‑weighted average price of 1,648.10p. The shares will be held as treasury shares.
Since 30 September 2025, GSK has purchased 5,727,500 shares. Following this transaction, GSK holds 253,192,344 shares in treasury and has 4,062,224,575 shares in issue (excluding treasury). Total voting rights are 4,062,224,575. The percentage of voting rights attributable to treasury shares is 6.23%.
FAQ
What is the current stock price of GSK PLC (GSK)?
What is the market cap of GSK PLC (GSK)?
